Traditional in vitro cell culture relies on simplified stimuli — single cytokines, LPS, synthetic growth factor cocktails — that were never designed to replicate the full complexity of human blood. A growing body of peer-reviewed evidence now demonstrates that applying human plasma or serum directly to cultured cells produces more physiologically relevant and translationally meaningful results. This guide explains the method, its applications, and the critical methodological decisions researchers must make.
Why Human Plasma and Serum — and Why Now?
The fundamental problem with conventional cell culture stimuli is biological reductionism. When a researcher adds LPS or a cytokine mix to a cell culture, they are exposing cells to one or a handful of defined mediators. Human blood, by contrast, contains thousands of proteins, lipids, metabolites, hormones, coagulation factors, complement proteins, immunoglobulins and growth factors acting simultaneously.
A 2025 review published in Clinical and Translational Science (Cela et al., PMC11864229) summarises more than 40 studies in which human plasma or serum was applied directly to cultured cells as a physiologically complex stimulus. The findings are consistent: human-derived blood fractions outperform simplified stimuli in reproducing in vivo cellular responses across a wide range of disease models — sepsis, COVID-19, COPD, diabetic ketoacidosis, liver disease and cancer.
The practical consequence for research purchasing is straightforward: labs running translational disease models increasingly need access to well-characterised human plasma and serum — not just as a supplement, but as the primary experimental stimulus.
Plasma vs. Serum — Which One for Your Model?
The choice between plasma and serum is the first decision and one of the most important. It is not merely a matter of preference — the two fractions differ fundamentally in composition and behaviour in cell culture.
Human plasma is collected with anticoagulant before centrifugation. It retains fibrinogen and all coagulation factors. Applied to cell culture at higher concentrations (≥20% v/v), plasma can induce clotting when anticoagulant activity is overcome by divalent cations in the culture medium. This risk is particularly relevant with EDTA and citrate anticoagulants. Heparin plasma avoids this problem because heparin inhibits thrombin independently of the medium composition — but heparin carries its own risks at high concentrations, including disruption of cell adhesion and interference with signalling pathways. The consensus recommendation from the literature is a minimum heparin concentration of 0.25 IU/mL to prevent coagulation while minimising off-target effects.
Human serum is obtained after natural or induced clotting. It lacks fibrinogen and coagulation factors — but gains additional growth factors released during platelet degranulation (PDGF, TGF-β, EGF). This makes off-the-clot (OTC) serum particularly valuable for applications where maximal growth factor content is required. Serum does not carry the clotting risk in cell culture that plasma does, and its behaviour across a broader range of concentrations is more predictable.
The practical recommendation: use serum when studying growth, proliferation, differentiation and signalling responses to physiological blood composition. Use plasma when the research question specifically involves coagulation factors, complement proteins or disease-state components that are degraded or altered by the clotting process.
Anticoagulant Selection for Plasma — A Decision That Affects Your Results
If plasma is the correct choice for your model, the anticoagulant must be specified carefully. The three standard formats each carry implications for cell culture:
| Anticoagulant | Mechanism | Suitable For | Avoid When |
|---|---|---|---|
| EDTA (K2/K3) | Irreversible Ca²⁺/Mg²⁺ chelation | Immunoassay, haematology, general IVD | Coagulation assays; can be overcome by media cations at high plasma % |
| Citrate (3.2%/3.8%) | Reversible Ca²⁺ chelation | Coagulation studies; calcium-restorable clotting | High concentrations in cell culture (clotting risk) |
| Heparin (Li/Na) | Thrombin inhibition — independent of media | Cell culture at ≥20% v/v; most translational models | PCR assays; MSC culture at high concentrations |
| ACD-A | Citrate + dextrose | Cell therapy, PBMC, platelet preparations | Routine clinical chemistry |
For disease-state models using plasma as the primary stimulus — the approach described in the Cela et al. review — heparin plasma at a minimum of 0.25 IU/mL is generally the most appropriate choice, as it prevents coagulation without the calcium-dependent limitations of EDTA and citrate.
Concentration Protocols — How Much Plasma or Serum to Add?
Concentration is one of the most variable parameters in the published literature, ranging from 0.5% to 100% v/v depending on cell type and experimental objective. The Cela et al. review identifies a clear logic:
High concentrations (≥20% v/v) are appropriate for cells that are directly exposed to blood in vivo — endothelial cells, circulating immune cells, vascular smooth muscle cells. These concentrations produce rapid, near-maximal cellular responses over short stimulation periods (1–12 hours). In sepsis models, 20% plasma from septic patients induced measurable endothelial hyperpermeability within 8 hours.
Low concentrations (≤5% v/v) are appropriate for parenchymal cells not directly exposed to systemic circulation — fibroblasts, myoblasts, hepatocytes. These concentrations allow observation of effects over extended time periods (24–168 hours) and more closely replicate the diluted concentration of plasma reaching tissues outside the vascular compartment.
20% v/v emerges as the optimal starting point for most endothelial and immune cell models — high enough to elicit robust responses, low enough to avoid complement-mediated cytotoxicity and coagulation artefacts.
For serum, the same logic applies with the added advantage that clotting risk is absent, allowing higher concentrations to be tested with greater confidence.
Disease-State Applications — Where the Method Delivers the Most Value
The most compelling use case for human plasma and serum as cell culture stimuli is in modelling specific disease states. The key finding from the literature is that disease-state plasma and serum reproduce cellular responses that simplified stimuli — individual cytokines, LPS — cannot reliably replicate.
Sepsis models have generated the most published data. Septic plasma applied to endothelial cells (HUVEC, HPMVEC) at 10–20% v/v consistently induces increased permeability, ROS production, monocyte adhesion and cytokine release — responses that correlate with clinical disease severity. Critically, DKA plasma induced oxidative stress in cerebrovascular endothelial cells, while a matched DKA cytomix at equivalent cytokine concentrations did not — demonstrating that the disease-state plasma contains oxidative-stress-inducing factors absent from simplified reconstituted stimuli.
COVID-19 models showed that plasma from critically ill patients reduced viability of pulmonary microvascular endothelial cells within one hour, while plasma from recovered patients had no such effect — a disease-severity distinction that could not have been replicated with a fixed cytokine stimulus.
COPD and smoking models used serum from smokers to demonstrate reduced endothelial migration, eNOS dysfunction and cardiovascular disease gene expression in HUVEC — a model that directly overcomes the physiological irrelevance of exposing endothelial cells directly to cigarette smoke in vitro.
Metabolic and exercise physiology has adopted human serum as the primary stimulus for muscle cell models — tracking the effects of fed vs. fasted states, exercise, and ageing on myotube protein synthesis and differentiation. The approach requires serum from individual or matched-pool donors to be applied to C2C12 or LHCN-M2 cells, reproducing systemic metabolic environments without in vivo animal experiments.
Biological and Lifestyle Variables — What to Control For
Human plasma and serum are not uniform reagents. Their composition varies systematically with donor age, sex, BMI, medication use, dietary state and exercise history. This variability is both the strength and the challenge of the method.
Key variables documented in the literature include: sex hormone differences between male and female donors (oestrogens, progesterone, FSH/LH vary cyclically in female donors and can activate steroid receptors in cultured cells); age-related changes in albumin concentration, cytokine baseline and metabolite profiles; and BMI-associated alterations in plasma proteome including leptin and FABP4.
The practical implications for experimental design: match donors by age and sex when comparing disease and control groups. Use male-only donor pools when hormonal variability would confound the results — a direct parallel to the preference for Human Serum OTC Type AB Male in CAR-T and ATMP manufacturing protocols. Consider pooled plasma from multiple donors to reduce individual variability in baseline studies, or single-donor units when the individual donor response is the subject of investigation.
Heat Inactivation — A Common Error to Avoid
Heat inactivation of human plasma or serum at 56°C for 30 minutes is standard practice for FBS preparation in many laboratories. Applying the same step to human plasma or serum intended as a disease-state stimulus is a significant methodological error. Heat inactivation denatures cytokines, growth factors and other signalling proteins — the very components that make the disease-state stimulus biologically meaningful. If you are using human plasma or serum as a stimulus to model disease, do not heat-inactivate it.
The only valid reason to heat-inactivate human serum for cell culture is complement depletion in models where complement-mediated cytotoxicity would be a confounding variable — and in disease-state models, complement activity is often itself a component of the pathological response being studied.
Practical Recommendations for Source Material
The quality and documentation of the human plasma or serum used as stimulus directly affects the reproducibility and regulatory acceptability of the results. Key requirements:
- Full viral screening per unit — HIV-1/2, HBsAg, HCV, Syphilis at minimum; NAT screening (HIV-1 RNA, HCV RNA, HBV DNA) for applications requiring higher safety standards
- Defined anticoagulant — specify at order and document in the methods section; results are not comparable across anticoagulant formats
- Documented donor demographics — age range, sex, blood group; essential for reproducibility and matched-cohort designs
- Single-donor units for disease-state reference panel work requiring per-donor traceability
- Pooled lots for baseline stimulation where inter-donor variability should be minimised
- Storage at −80°C when labile factors (coagulation factors, complement, labile cytokines) must be preserved; −20°C is acceptable for most general serum applications
SeamlessBio Human Plasma and Serum for Translational Research
SeamlessBio supplies human plasma and serum from certified EU and US donor centres in the formats and specifications required for translational disease models:
- Human Plasma — Pooled — EDTA, heparin or citrate; EU or US origin; bulk lots available; NAT screening on request
- Human Plasma — Single Donor — per-unit viral screening; full donor traceability; disease-state plasma sourced on request
- Human Plasma — Type AB Male — no anti-A/B antibodies; male donors only; EDTA, citrate or ACD-A; for cell therapy and immunologically sensitive models
- Human Serum OTC Type AB Male — off-the-clot; maximum growth factor content; the reference grade for CAR-T, NK cell and MSC protocols
- Human Serum Standard — mixed donors; cost-effective; heat inactivated or gamma irradiated on request
- Human Serum Delipidated — lipid-free matrix for lipemia interference studies
All products ship with Certificate of Analysis, Certificate of Origin, MSDS and viral screening report. Batch reservation with no prepayment. No minimum order quantity.
Request a sample or quote: info@seamlessbio.de · +49 851 37932226
References
Cela E, Patterson EK, Gill SE, Cepinskas G, Fraser DD. Application of Human Plasma/Serum to Cell Culture In Vitro: A Translational Research Approach to Better Define Disease Mechanisms. Clin Transl Sci. 2025. PMCID: PMC11864229. DOI: 10.1111/cts.70161
Allen SL, Elliott BT, Carson BP, Breen L. Improving physiological relevance of cell culture: the possibilities, considerations, and future directions of the ex vivo coculture model. Am J Physiol Cell Physiol. 2023;324(2):C420–C427. PMCID: PMC9902212.
SeamlessBio GmbH, Passau, Germany. This article is for scientific informational purposes. Product specifications and availability on request.
English 
Deutsch